Datamonitor''s Drugs of Tomorrow 2002: Depression - A Pipeline Driven by Side Effect Profile provides a comprehensive review of drugs in development for the treatment of depression. You will gain access to: • Detailed analysis of drugs in late stage development (stage II and above), including clinical and marketing profiles • Analysis of key compounds in early stage development • Revenue forecasts for key drugs up to 2009 • Alternative forecasts in the event of selected scenarios up to 2009 • The impact of new compounds and novel classes on the antidepressant market as a whole and individual brands within this market • Opinion leader comment about vital issues raised in the analysis Research Methodology: Datamonitor''s Drugs of Tomorrow analyses are based on extensive secondary and primary research into compounds in development for the relevant disease. Research is conducted by an in-house team who interview over 1000 employees from approximately 600 companies to establish an extensive database of product sales figures across 26 therapeutic areas. The following steps are carried out for each Drugs of Tomorrow research project: • Key points of information on drugs in the pipeline are compiled by a research team • The pre-clinical and clinical data of the compounds is complied and analyzed • The analysis is discussed with opinion leaders and amended as appropriate • Data validation through key company contacts to validate research findings Structure AND Scope: Patient Potential in Depression -Examines trends in the prevalence, diagnosis and comorbidities of the disease. R&D Approach Analyzes the different classes of antidepressants in development and provides a narrative of the tools used in clinical trials and a critique of how the trials are designed. Pipeline Overview Analyzes trends in the development programs and suggests marketing strategies for compounds and licensing potential for manufacturers. Late Stage Drug Analysis Analyzes antidepressants in late stage development and provides insight into the clinical data, marketing strength and impact on the current gold standard. Early Stage Drug Analysis Analyzes promising early stage antidepressants in terms of the scientific premise of the development programs and their potential to differentiate from current and late stage antidepressants. Market Forecasts Provides revenue forecasts for key compounds in development and also alternative forecasts in the event of major impacting factors
